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Abstract
Background: Rheumatism represents any disease condition marked with inflammation and pain in the joints,
muscles, or connective tissues. Many traditional Chinese drugs have been used for a long time to treat rheumatism.
However, a comprehensive information source for these drugs is still missing, and their anti-rheumatism
mechanisms remain unclear. An ontology for anti-rheumatism traditional Chinese drugs would strongly support the
representation, analysis, and understanding of these drugs.
Results: In this study, we first systematically collected reported information about 26 traditional Chinese decoction
pieces drugs, including their chemical ingredients and adverse events (AEs). By mostly reusing terms from existing
ontologies (e.g., TCMDPO for traditional Chinese medicines, NCBITaxon for taxonomy, ChEBI for chemical elements,
and OAE for adverse events) and making semantic axioms linking different entities, we developed the Ontology of
Chinese Medicine for Rheumatism (OCMR) that includes over 3000 class terms. Our OCMR analysis found that these
26 traditional Chinese decoction pieces are made from anatomic entities (e.g., root and stem) from 3 Bilateria
animals and 23 Mesangiospermae plants. Anti-inflammatory and antineoplastic roles are important for anti-
rheumatism drugs. Using the total of 555 unique ChEBI chemical entities identified from these drugs, our ChEBI-
based classification analysis identified 18 anti-inflammatory, 33 antineoplastic chemicals, and 9 chemicals (including
3 diterpenoids and 3 triterpenoids) having both anti-inflammatory and antineoplastic roles. Furthermore, our study
detected 22 diterpenoids and 23 triterpenoids, including 16 pentacyclic triterpenoids that are likely bioactive
against rheumatism. Six drugs were found to be associated with 184 unique AEs, including three AEs (i.e., dizziness,
nausea and vomiting, and anorexia) each associated with 5 drugs. Several chemical entities are classified as
neurotoxins (e.g., diethyl phthalate) and allergens (e.g., eugenol), which may explain the formation of some TCD
AEs. The OCMR could be efficiently queried for useful information using SPARQL scripts.
Conclusions: The OCMR ontology was developed to systematically represent 26 traditional anti-rheumatism
Chinese drugs and their related information. The OCMR analysis identified possible anti-rheumatism and AE
mechanisms of these drugs. Our novel ontology-based approach can also be applied to systematic representation
and analysis of other traditional Chinese drugs.
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Background
Rheumatic diseases are among the oldest diseases recog-
nized. In the fourth century B.C., such diseases were first
recognized by Hippocrates. In about the first century
A.D., the term “rheuma” was first introduced to represent
a flow of pain through joints of the body [1]. The word
“rheumatism” appeared about 300 or 400 years ago, and
subsumed both articular and non-articular musculoskel-
etal conditions. In 1802, William Heberden described the
rheumatism as a common name for many aches and pains
owing to very different causes [2]. More than 100 different
conditions could be labelled as rheumatic diseases, includ-
ing rheumatoid arthritis, osteoarthritis, systemic lupus er-
ythematosus, scleroderma, osteoporosis, back pain, gout,
fibromyalgia and tendonitis [3]. Rheumatoid arthritis, one
of the most common rheumatic diseases, is characterized
by persistent synovitis, systemic inflammation, and auto-
antibodies. Approximately 1% of the human population in
the world is afflicted by rheumatoid arthritis [4]. Existing
drugs for treating rheumatism include NSAID (non-ster-
oidal anti-inflammatory drug) and steroids for controlling
symptoms, and disease-modifying anti-rheumatic drugs
(DMARDs) (e.g., methotrexate and leflunomide) for inhi-
biting the underlying immune process and long-term
damages [4–6]. However, these drugs are in general far
from satisfactory in terms of effectiveness and safety.
From over a thousand years of experience, many trad-
itional Chinese drugs (TCDs), most of them made from
Chinese herbs, have been found to be effective in treating
rheumatic diseases. For example, Tripterygium wilfordii
Hook F (TwHF), also called Common Threewingnut Root,
Lei Gong Teng and Thunder God Vine, is a Chinese trad-
itional remedy used to treat many rheumatic diseases such
as rheumatoid arthritis, systemic lupus erythematosus,
and psoriasis [7]. TwHF extract inhibits the production of
cytokines and other mediators from mononuclear phago-
cytes by blocking the upregulation of a number of proin-
flammatory genes, including TNFα, COX2, interferon-γ,
IL-2, prostaglandin, and iNOS [8, 9]. The therapeutic and
adverse effects of the preparation are thought to be due to
triptolide and tripdiolide, two diterpenoid compounds
with epoxide groups and have immunosuppressive and
anti-inflammatory effects of similar efficacy in vivo and in
vitro [10–12]. The root of Tripterygium hypoglaucum, also
called Tripterygii Hypoglauci Radix TCD, contains similar
chemical compositions and have similar clinical efficacy
compared with TwHF [13]. Other herbs, such as Stepha-
nia tetrandra, have proved to be effective in treating
rheumatic diseases [14].
1Although the anti-rheumatism Chinese drugs have sig-
nificant therapeutic effects, many of them induce adverse
events (possible side effects). For example, Common Three-
wingnut Root TCD, extracted from TwHF, has proved to
cause diarrhea, hair loss and nausea in some patients. Even
the low dose (180 mg) of ethanol/ethyl acetate extract of
TwHF can cause 1–3 loose stools per day, which lasts for
1–3 days [9]. Tripterygii Hypoglauci Radix TCD can also
cause some common adverse events (AEs), such as nausea,
disturbances, drowsiness, and paresthesia [15]. Both Trip-
terygii Hypoglauci Radix TCD and Common Threewingnut
Root TCD are associated with reproductive system AEs
such as necrospermia and hypomenorrhea [16]. Aconitum
carmichaelii is commonly used in clinics for rheumatic
diseases such as rheumatic fever and painful joints [17].
However, inadequate boiling time of A. carmichaelii
Debeaux can cause aconitine poisoning [18].
The anti-rheumatism and AE mechanisms of traditional
Chinese drugs (TCDs) still remain unclear. Overall, exist-
ing western medicine drugs (e.g., non-steroidal anti-TNF
drugs and COX-2 inhibitors) have simple active ingredi-
ents and function through anti-inflammatory and immune
suppressive mechanisms [19–21]. However, each TCD
typically contains a number of chemical elements which
may interact with each other. The functions of these dif-
ferent chemical elements and their interactions are largely
unknown. For example, many anti-rheumatism TCDs,
such as Common Threewingnut Root TCD [16], have also
been used to treat cancer. Studies have also associated
rheumatism with neoplastia and cancer [22–24]. However,
it is still unclear what anticancer chemical elements exist
in anti-rheumatism TCDs and how they possibly contrib-
ute to the combined anti-rheumatism effects and AEs.
In the big data and IT era, a biomedical ontology is a set
of human- and computer-interpretable terms and rela-
tions that represent the entities in a specific biomedical
domain and how these entities are related. Ontologies
have played a critical role in biomedical data
standardization, sharing, and analysis [25–28]. Many on-
tologies can be used to study TCDs. For example, the In-
stitute of Information on Traditional Chinese Medicine in
China has recently developed the TCM Decoction Pieces
Ontology (TCMDPO; https://github.com/TCMOntology/
TCMDPO), which can be used to represent TCDs. The
NCBITaxon is an organism taxonomy ontology based on
the NCBI Taxonomy system [29]. Plant Ontology (PO) de-
scribes plant anatomy, morphology and the stages of plant
development [30]. The integrative cross-species anatomy
ontology UBERON covers anatomical structures in ani-
mals [31]. The Chemical Entities of Biological Interest
(ChEBI) ontologically represents and classifies over 50,000
molecular entities, esp. small chemical compounds, which
are either products of nature or synthetic products used
to intervene in the processes of living organisms [32]. The
relationships among these chemical entities, their parent
terms, and biological roles are also defined in ChEBI. The
Ontology of Adverse Events (OAE) is a community-based
biomedical ontology that represents various AEs after
medical interventions (e.g., drug administration) [33].
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These ontologies can be reused and integrated to repre-
sent and study anti-rheumatism TCDs.
In this study, we report our research of systematic in-
formation collection and development a community-
driven Ontology of CM for Rheumatism (OCMR) that
ontologically represents 26 anti-rheumatism Chinese
drugs, their chemical ingredients, AEs, and related infor-
mation. OCMR is developed by reusing many terms
from existing ontologies (including those mentioned
above) and using the state-of-the-art ontology engineer-
ing technologies [25, 27, 28, 34]. A systematical analysis
of the OCMR-represented information allows us to gen-
erate new insights about these Chinese drugs.
Methods
Identification of anti-rheumatism TCDs and their related
information
The identification of 26 anti-rheumatism TCDs was based
on our own knowledge and from references, and all our an-
notated results were recorded in an Excel file (Additional file
1). For eachTCD, the information we manually annotated in-
cluded organism, anatomic entity, chemical ingredients, and
AEs. The information of chemical ingredients for each TCD
was extracted from reliable resources, mostly from peer-
reviewed journal articles. The references for extracting the
chemical ingredients are provided in the Additional file 1.
We then mapped our identified information to correspond-
ing ontologies. Specifically, TCDs were mapped to the TCM
Decoction Pieces Ontology (TCMDPO; https://github.com/
TCMOntology/TCMDPO), organisms mapped to NCBI-
Taxon [29], animal anatomical entities to UBERON [31],
plant anatomical entities to PO [30], chemicals to ChEBI
[32], and AEs to OAE [33]. For those chemicals without
ChEBI IDs, we submitted requests to ChEBI website (https://
www.ebi.ac.uk/chebi/) to obtain new ChEBI IDs.For those
AE terms not found in OAE, we added new OAE terms
based on the standard OAE development procedure [33].
OCMR ontology generation
The OCMR ontology design follows the Open Biomed-
ical Ontologies (OBO) Foundry principles (e.g., openness
and collaboration) [34]. Protégé 5.0 OWL ontology edi-
tor (http://protege.stanford.edu/) was used for ontology
editing. OWL represents the format of W3C standard
Web Ontology Language (OWL2) (https://www.w3.org/
TR/owl-guide/). Ontofox (http://ontofox.hegroup.org/)
[35] was used to extract subsets of related terms from
different ontologies. In addition, we used Ontorat
(http://ontorat.hegroup.org/) [36] to quickly add the an-
notations and relations between different entities.
OCMR access, visualization, and licensing
The OCMR project website is located at GitHub:https://
github.com/biomedontology/ocmr/. OCMR was also
deposited in Ontobee (http://www.ontobee.org/ontology/
OCMR) and NCBO BioPortal (http://bioportal.bioontolo-
gy.org/ontologies/OCMR). The OCMR source code is
freely available under the Creative Commons 3.0 License
(http://creativecommons.org/licenses/by/3.0/), which al-
lows OCMR users to freely distribute and use OCMR.
OCMR ontology SPARQL query and knowledge analysis
The Ontobee SPARQL query web page (http://www.on-
tobee.org/sparql) was used to query OCMR to address
specific questions. The knowledge stored in the OCMR
ontology was also analyzed under the Protégé OWL edi-
tor and using Tableau (https://www.tableau.com/).
Results
Collection of data related to 26 anti-rheumatism trad-
itional Chinese drugs (TCDs)
In total, we identified 26 anti-rheumatism TCDs (Fig. 1 and
Additional file 1). These TCDs are made from anatomic
parts (mostly from root or stem) of 26 different animal and
plant organisms. Three TCDs were from animals, i.e., tiger
bone, black-tail snake, and silk-worm droppings. The others
were extracted from different plants (Fig. 1). For each TCD,
we manually identified chemical ingredients and AEs re-
ported from peer-reviewed articles (Additional file 1). These
resources then became the basic information of our later
ontology modeling, representation, and systematic analyses.
Our study identified 875 unique chemical elements in
these 24 of these 26 TCDs. In our study, no chemical
elements were found to be associated with Oriental Varie-
gated Coralbean Bark and Siegesbeckia Herb Chinese drugs
(Fig. 1). Many of these chemicals did not have ChEBI IDs.
Since many of these chemical elements initially did not exist
in ChEBI [32], we requested for 162 new ChEBI additions of
these chemical entities. Fig. 1 listed the numbers of ChEBI-
recorded chemical components for individual TCDs. For ex-
ample, Common Threewingnut Root TCD has 47 chemical
entities, Tripterygii Hypoglauci Radix TCD has 81 chemical
entities, and Common Floweringqince Fruit TCD has the
largest number of 125 chemical components (Fig. 1). In
total, 555 unique ChEBI IDs were identified from a total of
708 chemical components with ChEBI IDs.
Only 6 TCDs were identified to have various AEs (Fig. 1).
These 6 TCDs are associated with 262 AEs, among which
184 are unique. These 6 TCDs and the number of their as-
sociated AEs include Common Threewingnut Root TCD
(abdominal pain AE, anorexia AE, and gastritis AE), Trip-
terygii Hypoglauci Radix TCD (nausea and vomiting AE,
rash AE, and amenorrhea AE), Nux Vomica TCD, Ovient-
vine Stem TCD, Debark Peony Root TCD, and Prepared
Common Monkshood Branched Root TCD (Fig. 1). In
total, 178 AEs were mapped to OAE. We also added to
OAE 6 AEs not initially identified in OAE based on the
standard OAE development procedures [33].
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OCMR design and development
Figure 2 shows the basic top-level hierarchical structure of
OCMR. Specifically, OCMR uses the Basic Formal Ontol-
ogy (BFO) [37] as the upper level ontology. BFO contains
two branches, continuant and occurrent. The continuant
branch represents time-independent entities such as mater-
ial entity and their quality and roles, and the occurrent
branch represents time-related entities such as process and
time. Since BFO has been adopted by over 100 biomedical
ontologies, the usage of BFO allows OCMR easily and ef-
fectively integrated with other ontologies. In OCMR, 555
chemical elements of individual TCDs were mapped to the
chemical element terms in the ChEBI ontology. Since
higher level terms and relations related to these 555 chemi-
cals were also extracted and included in OCMR, OCMR
includes 2194 ChEBI terms. NCBITaxon terms are used to
represent organisms. Animal tissues and organs are repre-
sented using UBERON, and plant tissues are represented
using PO. Since all 26 anti-rheumatism TCDs are decoction
pieces, we extracted from the TCMDPO ontology to repre-
sent corresponding TCDs.
Figure 3 provides a general design pattern for a specific
anti-rheumatism TCD. Different from hierarchical relations
(Fig. 2), this design pattern logically links related terms
across different hierarchical structures in OCMR. The se-
mantic relations among different terms are generated using
axioms. Figure 4 shows many axioms that link the Common
Threewingnut Root TCD to different classes (e.g., chemical
entities, AEs) through specific relations. For example, the
following axiom defines that the TCD has triptolide as its
Fig. 1 26 anti-rheumatism traditional Chinese drugs studied in this project
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ingredient part: ‘has part’ some Triptolide. The relation ‘par-
ticipates in’ is used to represent a TCD participating in an
AE, for example, Common Threewingnut Root TCD: ‘partici-
pates in’ some ‘abdominal distension AE’ (Fig. 4).
The relationships between chemical entities and their bio-
logical/application roles, which provide critical information
in this study, are represented in ChEBI and OCMR using the
object property ‘has role’. For example, according to the
ChEBI definition, triptolide has a role as an anti-
inflammatory agent. ChEBI represents such a relation of trip-
tolide as: ‘has role’ some ‘anti-inflammatory agent’. In here
‘anti-inflammatory agent’ is classified in ChEBI as an applica-
tion role. With the relation definitions between TCD, chem-
ical entities, and biological/application roles, we are able to
identify important chemical entities with specific roles, which
may indicate key mechanisms of anti-rheumatism and AEs.
Fig. 2 Top level OCMR hierarchy. To make the relations simple and clear, some intermediate terms such as those terms in between Eukaryota
and Triterygium wilfordii are not shown
Fig. 3 General ontology design pattern for representing the relations among terms in OCMR
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As described in the Ontobee OCMR statistics page
(http://www.ontobee.org/ontostat/OCMR), OCMR con-
tains 3359 class terms, 12 object properties, 116 annota-
tion properties, and 10 instances. As illustrated above,
OCMR also generated many logical axioms to link terms
imported from different existing ontologies. The addi-
tions of these new axioms are based on our manually
annotated data (Additional file 1).
In the following sections we will describe our detailed
analyses of different OCMR components associated with
these anti-rheumatism TCDs.
Classification and organism sources of 26
anti-rheumatism TCDs
Figure 4 shows the TCMDPO classification of the 26 anti-
rheumatism TCDs in OCMR (https://github.com/TCMOn-
tology/TCMDPO). These 26 TCDs are classified into four
subclasses. Among them 23 TCDs belong to the subclass of
‘TCM dispelling pathogenic wind and dampness drug’.
Interestingly, the two Tripterygium species T. wilfordii and
T. hypoglaucum are classified under two different
subcategories, that is, T. wilfordii TCM is classified as a
winddamp-dispelling and heat-clearing drug, and T. hypo-
glaucum as a wind-damp dispelling and cold-dispersing
drug (Fig. 4). This observation indicates that two TCDs
under the same genus can have different functions (in this
case, two Tripterygium species drugs but one heat-clearing
function and the other cold-dispersing function), suggesting
other differences between these two species contribute to
the differences. Another interesting observation is that
there are three TCD categories each of which only has one
TCD (Figs. 1 and 4). Specifically, Nux Vomica TCD, which
is made from the seed of Strychnos nux-vomica, belongs to
the promoting blood circulation and removing blood stasis
drug. Debark Peony Root TCD, made from Paeonia
lactiflora Pall, is classified as a TCM supplementing and
boosting drug. Prepared Common Monkshood Branched
Root TCD, made from Aconitum carmichaelii, belongs to a
TCM warming interior drug. All the other 23 TCDs belong
to other 3 categories. Such an observation suggests that al-
though the functions of most anti-rheumatism TCDs are
grouped under 3 major categories, other anti-rheumatism
TCDs have different TCD functions.
Our NCBITaxon taxonomy-based analysis found that
among the 26 organisms, two are vertebrate animals (i.e.,
Amniota), including tiger (i.e., Panthera tigris) and snake (i.e.,
Ptyas dhumnades), and one is silkworm (i.e., Bombyx mori)
(Fig. 5a). In addition to these 3 Bilateria animals, the other
23 organisms belong to Mesangiospermae plants (Fig. 5a).
Sixteen of these anti-rheumatism TCM plant organisms be-
long to the subdivision of Pentapetalae, including the two
Tripterygium species T. wilfordii and T. hypoglaucum (Fig.
Fig. 4 Overview of anti-rheumatism TCDs in OCMR. The left side of the screenshot shows the overview of 26 anti-rheumatism TCDs. The right
side of the screenshot shows the annotations and axioms associated with the Common Threewingnut Root TCD. Axioms are generated to
represent the relations between this TCD and terms from different ontologies (e.g., NCBITaxon, PO, ChEBI, TCMDPO, and OAE)
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5b). This subdivision also includes two Rosales species Chae-
nomeles and Morus alba (Fig. 5b). It is unclear why the Pen-
tapetalae subdivision has so many anti-rheumatism drugs.
Note that the Ontofox program is able to identify the closest
ancestor for different taxonomy terms [35], such as the Bila-
teria as the closest ancestor for tiger, snake, and silkworm,
and Pentapetalae as the one for all plant organisms. Overall,
our NCBITaxon taxonomy ontology-based study provides
more insights in terms of the concrete taxonomical classifi-
cation of the TCD origins.
OCMR-based analysis of TCD chemical entities and anti-
rheumatism mechanisms
Our OCMR linkage between TCDs, TCD chemical ele-
ments, and the hierarchical relations among these chem-
ical elements provides an ideal platform to analyze those
chemicals with specific biological roles.
Our analysis has focused on the analysis of the TCD chem-
ical elements that have these two types of roles: anti-
inflammatory role and antineoplastic role. By analyzing all
chemical elements of these 26 TCDs and their applications/
biological or molecular roles, our study identified 18 chemical
elements having the anti-inflammatory role and 33 chemical
elements having the antineoplastic role (Table 1). Interest-
ingly, we also identified 9 chemical elements that have both
anti-inflammatory and antineoplastic roles (Table 1).
After analyzing the structural classification of the above
mentioned 42 chemical entities having anti-inflammatory
and/or antineoplastic roles, we identified 14 terpenoids
having the anti-inflammatory and/or anti-neoplastic roles
(Fig. 6a). The two known bioactive ingredients tripdiolide
and triptolide belong to diterpene triepoxide. Among
these terpenoids, 4 are diterpenoids (including tripdiolide
and triptolide), 7 are triterpenoids (more specifically, pen-
tacyclic triterpenoids). By examining all OCMR listed
chemical elements, we further found 22 diterpenoids and
23 triterpenoids (including 16 pentacylic triterpenoids
(Fig. 6c). The importance of these findings is described in
the Discussion section.
OCMR-based analysis of anti-rheumatism TCD AEs and
possible AE mechanisms
The information about AEs provided general safety is-
sues of anti-rheumatism TCDs. In total, 184 unique AEs
were identified to be associated with 6 TCDs (Additional
file 1). Figure 7a shows an overview of 184 unique AEs
associated with 6 TCDs. The top 20 AEs each associated
with at least 3 TCDs are labeled. Dizziness, nausea and
vomiting, and anorexia are associated with 5 drugs. Ten
AEs are associated with 4 drugs. Seven AEs are shared
by 3 drugs. To further study these AEs, we utilized the
OAE hierarchical structure to classify these 20 AEs into
various top-level AE classes in OAE (Fig. 7b). Eight of
these 20 AEs (7 of them being sensory capability AEs)
belong to the behavioral and neurological AE category.
There are 3 digestive system AEs and 2 skin AEs. The
remaining 7 AEs belong to different systems (Fig. 7b).
Fig. 5 The taxonomy of 26 organisms used for anti-rheumatism TCDs. Ontofox was used to generate the results with the option of
“includeComputedIntermediates”. The Protege OWL editor was used for visualization. Among the 26 organisms, 16 belong to the branch of
Pentapetalae. The anatomic labels next to the organism names represent the anatomic locations from where the Chinese medicines are made
from. Root is the most commonly used anatomic location
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Table 1 OCMR chemical ingredients having antineoplastic/anti-inflammatory roles
# Chemical ingredients ChEBI ID Chinese Medicine (Chinese name)
Ingredients with both of anti-neoplastic and anti-inflammatory role
1 4-terpineol CHEBI_78884 Common Floweringqince Fruit*
2 all-trans-retinoic acid CHEBI_15367 Silk-worm Droppings, Tiger Bone
3 botulin CHEBI_3086 Chinese Clematis Root, Common Floweringqince Fruit
4 betulinic acid CHEBI_3087 Chinese Taxillus Herb, Common Floweringqince Fruit, Debark Peony Root
5 celastrol CHEBI_63959 Common Threewingnut Root, Tripterygii Hypoglauci Radix
6 ethyl trans-caffeate CHEBI_132714 Nux Vomica
7 fangchinoline CHEBI_132893 Fourstamen Stephania Root
8 tripdiolide CHEBI_9740 Common Threewingnut Root
9 triptolide CHEBI_9747 Common Threewingnut Root, Tripterygii Hypoglauci Radix
Ingredients with anti-neoplastic role
10 (+)-sesamin CHEBI_66470 Acanthopanax Root Bark
11 (+)-syringaresinol CHEBI_47 Common Threewingnut Root
12 3,4-dihydroxybenzoic acid CHEBI_36062 Acanthopanax Root Bark, Chinese Taxillus Herb, Common Floweringqince Fruit, Nux Vomica
13 apigenin CHEBI_18388 Chinese Starjasmine Stem, Harlequin Glorybower Leaf
14 beta-elemene CHEBI_62854 Wooly Datchmanspipe Herb
15 daidzein CHEBI_28197 Chinese Clematis Root
16 emodin CHEBI_42223 Common Threewingnut Root
17 gallic acid CHEBI_30778 Common Floweringqince Fruit, Nux Vomica
18 genistein CHEBI_28088 Chinese Clematis Root
19 hesperetin CHEBI_28230 Chinese Clematis Root
20 hydroxytyrosol CHEBI_68889 Harlequin Glorybower Leaf
21 isoorientin CHEBI_17965 Largeleaf Gentian Root
22 luteolin CHEBI_15864 Common Floweringqince Fruit, Chinese Starjasmine Stem
23 maslinic acid CHEBI_66682 Common Floweringqince Fruit
24 methoxsalen CHEBI_18358 Doubleteeth Pubescent Angelica Root
25 morin CHEBI_75092 Mulberry Twig
26 morusin CHEBI_7005 Mulberry Ttwig
27 naringin CHEBI_28819 Chinese Starjasmine Stem
28 neohesperidin CHEBI_59016 Chinese Clematis Root
29 nobiletin CHEBI_7602 Chinese Clematis Root, Common Threewingnut Root
30 procyanidin B4 CHEBI_27589 Tripterygii Hypoglauci Radix
31 quercetin CHEBI_16243 Chinese Clematis Root, Common Floweringqince Fruit, Chinese Taxillus Herb
32 sciscllascilloside E-1 CHEBI_66439 Common Threewingnut Root
33 triptonide CHEBI_132267 Common Threewingnut Root
Ingredients with anti-inflammatory role
34 acteoside CHEBI_132853 Harlequin Glorybower Leaf
35 decanoic acid CHEBI_30813 Common Floweringqince Fruit
36 ferulic acid CHEBI_17620 Chinese Taxillus Herb, Nux Vomica
37 lupeol CHEBI_6570 Chinese Taxillus Herb, Nux Vomica, Silk-worm Droppings
38 maslinic acid CHEBI_66682 Common Floweringqince Fruit
39 procyanidin B3 CHEBI_75630 Trypterygii Hypoglauci Radix
40 tectorigenin CHEBI_9429 Chinese Clematis Root
41 triptonide CHEBI_132267 Common Threewingnut Root
42 fredelin CHEBI_5171 Tripterygii Hypoglauci Radix
Note: *, for each Chinese drug name (e.g., ‘Common Floweringqince Fruit TCD’), the end “TCD” word is ignored
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By analyzing the chemical entities and associated bio-
logical roles, we can identify possible AE mechanisms.
The most prominent side effects of T. wilfordii and T.
Hypoglauci extracts are their association with reduction
of reproductive functions including necrospermia, hypo-
menorrhea, and infertility [16]. Several anti-rheumatism
chemical ingredients, including triptolide, tripdiolide,
and triptolidenol, have been found to contribute to such
antifertility effects [16, 38]. These chemicals have been
contained in OCMR. Furthermore, our systematic
OCMR knowledge base analysis identified many more
neurotoxins and allergens. Interestingly, over 30 benzene
type chemicals are found, many of them are known neu-
rotoxins and allergens, such as eugenol (an allergen) [39,
40], diethyl phthalate (neurotoxin with possible adverse
reproductive outcomes) [41], and toluene (neurotoxin)
[42]. How these benzene chemical entities contribute to
known AEs associated with TCDs deserves more studies.
SPARQL query of the OCMR knowledge base
The OCMR ontology is formatted using the Web Ontol-
ogy Language (OWL) [43] format. The contents of the
OWL files can be expressed with Resource Description
Framework (RDF; https://www.w3.org/RDF/) triples and
stored in an RDF triple store database. The RDF data
model makes statements about resources in the form of
subject-predicate-object expressions (i.e., triples).
SPARQL (a recursive acronym for SPARQL Protocol
and RDF Query Language) [44] is used to retrieve data
stored in a RDF triple store. Since the OCMR ontology
has been stored in the Ontobee triple store, the Ontobee
SPARQL website (http://www.ontobee.org/sparql) could
be used to query the OCMR knowledge. Figure 8 pro-
vides an example of such a SPARQL query. As shown in
this example, a few lines of SPARQL code can be used
to identify the 33 antineoplastic chemical entities as in-
gredients of the anti-rheumatism Chinese medicines.
Discussion
This manuscript reports an interesting bioinformatics
project that started simply with the knowledge of a list
of anti-rheumatism TCDs. For the list of 26 TCDs, we
systematically and manually annotated peer-reviewed ar-
ticles and retrieved their associated organism sources
and anatomic locations in these organisms, chemical in-
gredients of these Chinese drugs, and AEs. With the
Fig. 6 Hierarchical analysis of chemical entities of anti-rheumatism TCDs based on ChEBI classification. a 14 chemicals with antineoplastic and/or
anti-inflammatory roles are lipids. Among these lipids, 12 are terpenoid chemicals, which include 4 diterpene triepoxides and 7 pentacylic
triterpenoids. In the subfigure, “a-i” represents anti-inflammatory role, and “a-n” represents antineoplastic role. To generate this screenshot,
Ontofox was used to generate a ChEBI subset using all 42 chemicals with antineoplastic and/or anti-inflammatory roles. The results were
visualized using the Protégé OWL editor. b The whole OCMR diterpenoid branch that has 22 chemical elements (including triptolide and
tripdiolide). c The whole triterpenoid branch in OCMR. This branch includes 23 chemical elements, among which are 16 pentacylic triterpenoids
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collected information, we generated the Ontology of
Chinese Medicine for Rheumatism (OCMR). The
OCMR systematically represents, organize, and inte-
grates all information related to these anti-rheumatism
TCDs. Our OCMR-based analysis was able to generate
many scientific insights in terms of the underlying
molecular mechanisms for the intended anti-
rheumatism and unintended AEs of these TCDs.
One major novelty of our ontology-based approach ex-
ists in that OCMR systematically integrates separate in-
formation learned from different branches of science in
a logical ontology format, supporting advanced data
Fig. 8 Example SPARQL query of OCMR. Performed on the Ontobee SPARQL website (http://www.ontobee.org/sparql), this example queried all
the chemical entities that have the antineoplastic agent role. In total 33 hits were identified, and only 7 are shown in this screenshot
Fig. 7 Analysis of AEs associated with anti-rheumatism TCDs. a Representation of all 184 unique AEs associated with 6 TCDs. The figure was generated
by Tableau. Each circle represents an AE. The size and color of circles represent how many drugs shared the AE. b Ontological representation of 20 AEs
(indicated by the sign *) each associated with at least 3 TCDs and their associated upper level AE terms. Ontofox was used to generate an OAE subset
containing these 20 AEs
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representation, integration, sharing, and analysis. The
simple lists of the terms of drugs, chemical elements,
and AEs (Additional file 1) are useful but their usage is
limited. By mapping these terms to existing ontologies
and extracting related information from the existing on-
tologies (i.e., TCMDPO, NCBITaxon, UBERON, PO,
ChEBI, and OAE), we were able to obtain deep back-
ground information including their higher layers of class
terms in different hierarchical structures and deep rela-
tions among these terms. Such extracted information
then becomes informative even to people without strong
backgrounds in these fields. For example, ChEBI pro-
vides additional information about different applications
and roles of chemical entities. The collection of total
chemicals associated with particular roles (e.g., anti-
inflammatory role) allows us to identify all possible
chemical entities containing such biological roles. In
addition, OCMR includes semantical axioms that logic-
ally link different terms in a computer-understandable
format. With all terms organized in an integrative
OCMR format, we were able to semantically query and
analyze the standardized knowledge to address scientific
questions.
Our OCMR ontology analysis identified useful insights
about anti-rheumatism mechanisms of TCDs. As dem-
onstrated in Table 1 and Fig. 6, our study identified
many chemical entities that have anti-inflammatory and/
or anti-neoplastic roles. Furthermore, we identified
many additional diterpenoids and triterpenoids as chem-
ical components of anti-rheumatism TCDs. Triptolide
and tripdiolide are two diterpenoids known to have anti-
inflammatory and antineoplastic roles [10–12, 45]. More
diterpenoids were identified in our study. Many triterpe-
noids have also been found to induce anti-inflammatory
effects [4, 46–49]. Triterpenoids have been known to be
useable as new promising anticancer drugs [50]. Inter-
estingly, the most prominent triterpenoids found in our
study are pentacyclic triterpenoids (Fig. 6c). A recent
study indicated that pentacyclic triterpenoids inhibit
IKKβ-mediated activation of NF-κB pathway [51]. The
NF-κB plays an important role in regulating various pro-
inflammatory and immune-regulatory cytokines, cyclo-
oxgenase-2, growth factors, and the apoptotic cascade.
Given these findings, the potential anti-rheumatism ef-
fects of different diterpenoids and triterpenoids (esp.
pentacyclic triterpenoids) deserve further informatics
and experimental investigations.
The association between anti-rheumatism TCDs and
antineoplastic chemical entities is unclear. Our study iden-
tified 33 antineoplastic chemical ingredients in anti-
rheumatism TCDs. This number nearly doubles the num-
ber (18) of anti-inflammatory chemicals detected from
our study. Many evidences have been available to associate
rheumatism with neoplastia and cancer [22–24]. However,
it is still unclear how rheumatic diseases are related to
neoplastic conditions [24] and how antineoplastic drugs
can help the treatment of rheumatic diseases. Our identifi-
cation of many antineoplastic chemical ingredients in
anti-rheumatism TCDs suggest that these antineoplastic
chemical ingredients might play an important role in com-
binatorial effects against rheumatism.
Unlike western chemical drugs, each TCD usually has
many chemicals whose roles in the drug effect are often
unknown. Therefore, it is difficult to identify or statisti-
cally analyze the chemicals significantly associated with
the positive anti-rheumatism effect and the negative AE
effects. However, based on the reported roles (e.g., anti-
inflammatory and antineoplastic roles) and mechanisms
of actions of many chemicals and chemical classifications,
we can make general hypotheses as generated and ex-
plained in this manuscript. Further conclusions will re-
quire experimental verifications in a laboratory animal
model(s) with careful controlled randomized study design.
In this study, we only curated, represented, and ana-
lyzed traditional Chinese drugs prepared from individual
anatomic sources of plant or animal. There are also vari-
ous combinations of crude drugs used for medication.
Such cases are more complicated in terms of its prepar-
ation, components, and mechanisms of actions. In
addition, it is likely some drugs and drug ingredients
interact with each other under specific conditions. Such
Chinese drug combinations, their formations and inter-
actions, and the intended and adverse effects of such
combinations will be considered in our future ontology-
based systematic studies.
Note that after the chemical components of the 26
TCMs are known, it is possible to use ChEBI to do many
analyses in terms of chemical classification and mechan-
ism of action study (Table 1, Figs. 5 and 6). Such
Ontofox-derived ChEBI subset generation and analysis
demonstrate another aspect of ontology usage. It is also
realized that without OCMR, the pure ChEBI-based
ontological analysis does not allow the direct linkages
and queries between chemicals, chemical groups, and
TCD drugs, which may diminish integrative applications
(e.g., chemical groupings based on more specific TCD
drug categories) where such linkages are necessary. In
addition to the chemical-based analysis, OCMR provides
many more features (e.g., NCBITaxon-based taxonomic
analysis) as described in the report. Furthermore, OCMR
provides a centralized and reusable knowledge base that
can support future revision, extension, storage, and ana-
lyses by users with more applications.
The ontology-based methods of anti-rheumatism TCD in-
formation representation and analysis described in this study
are applicable to other TCDs. Our study demonstrates the
usage of the traditional Chinese medicine TCMDPO ontol-
ogy. TCMDPO has collected 323 class terms and 4 object
Liu et al. BMC Systems Biology 2017, 11(Suppl 7):130 Page 123 of 174
properties. It contains various data related to TCDs, such as
their scientific names, natures, flavors, toxicity and channel
tropism. With a small section of the TCMDPO terms and
relations imported, OCMR significantly expand the informa-
tion of these imported TCDs with standardized organisms
from NCBITaxon, anatomic entities from PO and UBERON,
chemical entities from ChEBI, and AEs from OAE. Further-
more, OCMR logically links different terms with axiom defi-
nitions and builds all the information under an integrative
BFO-aligned framework. It is possible to extend other
TCMDPO drugs using the new strategies implemented in
this study. Such an integrative strategy will allow more inte-
grative usage and applications of TCMDPO drugs for more
advanced representation, standardization, integration, and
analysis of traditional Chinese drugs and their roles in treat-
ing various diseases.
Conclusions
In this study, we first collected 26 anti-rheumatism trad-
itional Chinese drugs and their related information includ-
ing reported chemical elements and associated adverse
event (AEs). Based on the manually annotated data, we de-
veloped an Ontology of Chinese Medicine for Rheumatism
(OCMR). OCMR has three main features: (i) By importing
related terms from existing ontologies, OCMR represents
hierarchical structures of these traditional Chinese drugs,
their associated organisms, anatomic locations, chemical
entities and their roles, and AEs. (ii) OCMR uses semantic
axioms to link terms from different hierarchical structures
(e.g., drugs and chemical entities). (iii) OCMR integrates all
the terms and their relations in a BFO-aligned systemic
framework. Our OCMR ontology analysis identified many
chemical entities with anti-inflammatory and antineoplastic
roles, which may explain drug anti-rheumatism mecha-
nisms, and we also identified chemicals with neurotoxin or
allergen roles, which many explain drug AEs. Important
branches of chemical entities, such as diterpenoids and tri-
terpenoids, were also identified. Based on these findings, we
also propose new areas of future anti-rheumatism research.
This study represents the first study of using ontology to
systematically represent and analyze traditional Chinese
drugs, their chemical ingredients and associated roles, and
AEs. Such a method can also be applied to study other
traditional Chinese drugs.
Additional file
Additional file 1: An Excel file of all the detailed information. This Excel
file includes four spreadsheets. These spreadsheets cover the following
information:Spreadsheet 1: TCD-related organisms, organism IDs in
NCBITaxon. Spreadsheet 2: Chemical components in TCDs, ChEBI IDs, and
related references. Spreadsheet 3: TCD AEs including AE names, OAE AE
IDs, related references. Spreadsheet 4: TCD-specific anatomic locations in
organisms, and the PO and UBERON IDs corresponding to these ana-
tomic entities. (XLSX 93 kb)
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